首页> 外文期刊>Virology >A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus.
【24h】

A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus.

机译:颗粒病毒蛋白疫苗可降低病毒载量,并延缓马传染性贫血病毒攻击的免疫小马的疾病进展。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Immunization regimens that induce a broadly reactive cytolytic T lymphocyte (CTL) response specific for lentiviral antigens have emerged as the leading candidates in efficacy trials conducted in both animal modelshumans. To date, lentivirus vaccination strategies have overlooked one such immunization strategy, namely the use of particulate antigens. To evaluate the efficacy of targeting antigen into the phagocytic pathway to elicit a cell-mediated immune response to lentiviral antigens, we initiated the first study of a particulate-based vaccination protocol using a large animal model system. Gradient-purified equine infectious anemia virus (EIAV) was covalently coupled to glutaraldehyde-activated iron oxide beads. In vitro studies demonstrated the effectiveness of the inactivated whole virus particulate to prime antigen presenting cells for the activationexpansion of virus-specific CD8(+) CTL. The in vivo effectiveness of the particulate antigen was evaluated by experimental immunization of ponies. Ponies receiving the viral particulate vaccinechallenged with infectious EIAV had a delayed progression to diseasea reduced viral load compared with infected ponies that had not been vaccinated. Interestingly, in vitro virus-specific CTL activity was detected in only one of four immunized animals at the day of challenge. The beneficial effects of the particulate vaccine regimen were not clearly associated with any in vitro measurable parameters of the virus-specific cellular or humoral immune responses elicited by the vaccine at the day of challenge. However, within 3 weeks after virus challenge, anamnestic humoral responses characterized by a rapid emergence of neutralizing activity in the seruma predominance of conformationally dependent epitopes recognized by virus-specific antibodies were observed in the vaccinates. Taken together, further studies are clearly warranted in large animal model systems using a particulate-based vaccine regimen considering the beneficial effects of this regimen in our studythe protective effects of particulate antigen delivery in the murine model. Copyright 1999 Academic Press.
机译:诱导对慢病毒抗原特异的广泛反应性溶细胞性T淋巴细胞(CTL)反应的免疫方案已成为在两种动物模型中进行的功效试验的主要候选对象。迄今为止,慢病毒疫苗接种策略已经忽略了一种这样的免疫策略,即使用颗粒抗原。为了评估靶向抗原进入吞噬途径以引发针对慢病毒抗原的细胞介导的免疫反应的功效,我们启动了使用大型动物模型系统的基于颗粒的疫苗接种方案的首次研究。将梯度纯化的马传染性贫血病毒(EIAV)与戊二醛活化的氧化铁珠共价偶联。体外研究表明,灭活的完整病毒颗粒对抗原提呈细胞的激活可有效扩展病毒特异性CD8(+)CTL。通过实验性小马免疫来评估颗粒状抗原的体内有效性。与未接种疫苗的受感染小马相比,接受感染性EIAV感染的病毒颗粒疫苗的小马延缓了疾病进展,病毒载量降低。有趣的是,在攻击当天仅在四只免疫动物中的一只中检测到了体外病毒特异性CTL活性。颗粒疫苗方案的有益作用与在攻击当天疫苗引起的病毒特异性细胞或体液免疫应答的任何体外可测量参数没有明确关联。然而,在病毒攻击后的三周内,在疫苗中观察到记忆性体液反应,其特征是血清中以中和活性迅速出现,主要是病毒特异性抗体识别的构象依赖性表位。综上所述,考虑到该方案在我们的研究中的有益作用以及在小鼠模型中微粒抗原递送的保护作用,在大型动物模型系统中显然需要使用基于微粒的疫苗方案进行进一步的研究。版权所有1999,学术出版社。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号